A61K 47/545
Heterocyclic compounds
Official title: {Heterocyclic compounds (A61K47/558 takes precedence)}
A61K47/545 (Heterocyclic compounds) appears on 1,156 US grants and 2,295 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,156
- Published applications
- 2,295
- Assignees
- 974
- Inventors
- 5,064
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 9 | 0 |
| 1994 | 7 | 0 |
| 1995 | 9 | 0 |
| 1996 | 19 | 0 |
| 1997 | 11 | 0 |
| 1998 | 16 | 0 |
| 1999 | 11 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 2 |
| 2002 | 5 | 6 |
| 2003 | 3 | 11 |
| 2004 | 5 | 11 |
| 2005 | 5 | 11 |
| 2006 | 4 | 11 |
| 2007 | 4 | 9 |
| 2008 | 2 | 16 |
| 2009 | 3 | 14 |
| 2010 | 3 | 24 |
| 2011 | 10 | 26 |
| 2012 | 9 | 34 |
| 2013 | 17 | 41 |
| 2014 | 28 | 55 |
| 2015 | 36 | 82 |
| 2016 | 48 | 98 |
| 2017 | 63 | 94 |
| 2018 | 62 | 94 |
| 2019 | 73 | 147 |
| 2020 | 86 | 134 |
| 2021 | 78 | 184 |
| 2022 | 67 | 224 |
| 2023 | 93 | 270 |
| 2024 | 125 | 286 |
| 2025 | 117 | 229 |
| 2026 | 105 | 182 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Benzoheterocycle substituted tetrahydroisoquinoline compound6 Oct 2026US 12,752,011 B2Jiangxi Jemincare Group Co., Ltd
- EGFR degraders and associated methods of use6 Oct 2026US 12,752,012 B2BeOne Medicines | GmbH
- Near-infrared dyes and conjugates for targeting tumors6 Oct 2026US 12,752,023 B2Lahjavida, LLC
- VIPR2 antagonist peptide6 Oct 2026US 12,753,206 B2Ichimaru Pharcos Co., Ltd.
- Ionizable cationic lipid analog material and use thereof as drug delivery carrier29 Sep 2026US 12,746,288 B2Guangzhou Lide Biomedicine Technology Co., Ltd.
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Compounds and uses thereof8 Oct 2026US 2026/0306638 A1Foghorn Therapeutics Inc.
- Helicase degraders8 Oct 2026US 2026/0306641 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Stat degraders and uses thereof8 Oct 2026US 2026/0306642 A1Recludix Pharma, Inc.
Most cited
By later US patents
- Uncharged morpholino-based polymers having achiral intersubunit linkages1,700US 5,034,506 AAnti-Gene Development Group · 1991
- Alpha-morpholino ribonucleoside derivatives and polymers thereof900US 5,235,033 AAnti-Gene Development Group · 1993
- Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages851US 5,185,444 AAnti-Gene Deveopment Group · 1993
- Sequence-specific binding polymers for duplex nucleic acids786US 5,166,315 AAnti-Gene Development Group · 1992
- Sequence-specific binding polymers for duplex nucleic acids493US 5,405,938 AAnti-Gene Development Group · 1995